What Cost the Supercollider?

For decades, increasingly expensive particle-accelerator projects have been advocated in language almost identical to that now being used to promote the $6 billion superconducting supercoflider (SSC), including promises of "scientific leadership," "spin-offs," of technological and medical "breakthroughs," and so forth. But there is only meager evidence that past promises have been fulfilled and that present promises are any more credible. In a story on the SSC, The New York Times on January 19 s

Written byLawrence Cranberg
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Of course we need to put our best foot forward in the interests of science and technology, as the advocates of the SSC repeatedly state (see "Criteria for Scientific Choices," by Alvin M. Weinberg, Physics Today, March 1964). But that may be just the reason that we should not build the SSC if it will divert scientific manpower—whose supply is severely limited— from tasks with far more promise of making substantial contributions to our scientific and technological development. Japan spends nothing like the vast sums we have spent on particle research. West Germany, which also spends little, is the only country that has an inexpensive, cost-effective in-hospital accelerator facility for the treatment of cancer with fast neutrons—a goal which has thus far eluded our own accelerator establishment.

To many young physicists today, hunting for quarks with a gigantic accelerator may seem much more glamorous than doing materials research with bench-top ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies